Wells Fargo & Company Evolus, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Evolus, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 49,347 shares of EOLS stock, worth $690,364. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,347
Previous 34,841
41.63%
Holding current value
$690,364
Previous $564,000
3.55%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding EOLS
# of Institutions
169Shares Held
48.8MCall Options Held
57.2KPut Options Held
5.5K-
Perceptive Advisors LLC New York, NY5.15MShares$72 Million1.9% of portfolio
-
Tang Capital Management LLC San Diego, CA5MShares$69.9 Million4.14% of portfolio
-
Black Rock Inc. New York, NY4.01MShares$56.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.17MShares$44.4 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.13MShares$43.8 Million1.74% of portfolio
About Evolus, Inc.
- Ticker EOLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 56,094,800
- Market Cap $785M
- Description
- Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...